CHICAGO / OXFORD: Artificial intelligence-powered imaging from Brainomix has played a pivotal role in identifying the therapeutic benefit of ARG-007, a novel neuroprotective drug candidate, in patients suffering from severe acute ischemic stroke.
The analysis was conducted as part of a Phase II clinical study by Argenica Therapeutics, with Brainomix providing imaging standardisation and data interpretation through its Brainomix 360 Stroke platform.
By leveraging regulatory-cleared AI technology and a foundation-model-based imaging pipeline, Brainomix delivered robust baseline phenotyping and outcome analysis, addressing a longstanding challenge in stroke research: inconsistent assessment of stroke severity.
The AI-based evaluation demonstrated that patients with more extensive brain injury at baseline showed meaningful improvements when treated with ARG-007. These improvements were evident in early neurological recovery at 24 hours and reduced disability at 90 days.
Furthermore, treated patients exhibited smaller final infarct volumes, reinforcing the drug’s neuroprotective mechanism and potential to preserve brain tissue following acute ischemic events.
Dr Michalis Papadakis noted that incorporating AI-driven imaging early in clinical trials enhances the ability to detect treatment signals and identify patient populations most likely to benefit.
Dr Liz Dallimore added that the findings support a precision medicine approach for future ARG-007 trials, enabling better patient selection and increasing the likelihood of achieving meaningful clinical outcomes.